AdvisorShares Psychedelics ETF (PSIL) Dividend History

Dividend History

Pay Date Amount Ex Dividend Date Record Date
March 28, 2025 $0.16 03/21/2025 03/21/2025
December 30, 2024 $0.05 12/23/2024 12/23/2024
September 30, 2024 $0.11 09/23/2024 09/23/2024
September 29, 2023 $0.00 09/25/2023 09/26/2023
September 30, 2022 $0.05 09/26/2022 09/27/2022

Dividends Summary

  • AdvisorShares Psychedelics ETF has issued 5 dividend payments over the past 3 years
  • The most recent dividend was paid 71 days ago, on March 28, 2025
  • The first recorded dividend was paid on September 30, 2022
  • The highest dividend payout was $0.16 per share
  • The average dividend over this 3 year span is $0.08 per share
  • AdvisorShares Psychedelics ETF has increased its dividend payments by 201.48% since 2022

Company News

  • Cannabis And Psychedelics Industries: Summer's Over, Where Are We?

    The cannabis industry is awaiting a decision on rescheduling cannabis, which could impact its financial and regulatory landscape. The psychedelics industry is navigating the aftermath of a setback in MDMA research for PTSD, leading to potential consolidation and strategic shifts.

    Benzinga
  • Top and Flop ETFs of the First Half

    We have highlighted three ETFs each from the best and worst-performing zones in the first half of 2024.

    Zacks Investment Research
    Featured Companies: AAPL AMZN GBTC LITP MSFT NVDA SMH SPMO VIXY WBA
  • Best and Worst ETF Zones of Q2

    Technology remained the best-performing sector of the second quarter on the AI drive while energy lagged.

    Zacks Investment Research
    Featured Companies: BDRY SLVP UNG WEED WGMI
  • Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment

    A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients. Most stocks in the psychedelic space took a hit on Wednesday as a result of the ruling.The panel voted 9-2 that MDMA, when combined with talk therapy, is not effective in treating PTSD. The panel also voted 10-1 that the current benefits do not outweigh the potential risks of using the drug to treat mental issues.Some members of the panel, ...Full story available on Benzinga.com

    Benzinga
    Featured Companies: ATAI CYBN MNMD
  • Top & Flop ETFs of August

    August was an average-to-downbeat month for investors, mainly due to rising rates.

    Zacks Investment Research
    Featured Companies: BKCH CANE CTEC PFIX SARK TUR URNJ WEAT
Dividend data last updated 06/07/2025 22:00:24 UTC